Klar Ernst
Abteilung für Allgemeine, Thorax, Gefäß- und Transplantationschirurgie, Universitätsmedizin Rostock, Schillingallee 35, 18057, Rostock, Deutschland.
Chirurg. 2018 Oct;89(10):755-759. doi: 10.1007/s00104-018-0705-3.
The main goal of the Medical Device Regulation (MDR) is the improvement of patient safety by laying down rules concerning the approval of medical devices for human use in the European Union. The MDR contains an extension of the conformity assessment procedure for products in the higher risk categories IIb and III. The clinical testing and assessment are regulated more strictly by e.g. the scrutiny process conducted by expert panels following the technical certification. The demand for documentation is vastly increasing due to more detailed registration (UDI) and an extension of post-market surveillance. The German Society of Surgery (DGCH) and the German Society for Biomedical Engineering have already defined a staged concept for innovation testing and clinical assessment during finalization of the MDR that contains the highest level of patient safety while simultaneously maintaining the potential for innovation. Essential elements are present in the MDR and can be implemented in a targeted way. The 3‑year phase of national MDR-implementation must be used for a proactive adaptation. The DGCH is represented in the advisory council of the Federal Ministry of Health (BMG) by the Association of the Scientific Medical Societies in Germany (AWMF). The aim is a responsible harmonization of national structures with the regulations of the MDR by the construction of specific registries which should be the responsibility of medical societies. The early integration of health technology assessment will be of importance during the planning phase of product development to facilitate a positive decision on reimbursement.
《医疗器械法规》(MDR)的主要目标是通过制定有关欧盟境内人类使用医疗器械审批的规则来提高患者安全性。MDR对较高风险类别IIb和III类产品的合格评定程序进行了扩展。例如,技术认证后由专家小组进行的审查过程对临床试验和评估进行了更严格的监管。由于更详细的注册(唯一器械标识)和上市后监督的扩展,文件需求大幅增加。德国外科学会(DGCH)和德国生物医学工程学会在MDR定稿期间已经为创新测试和临床评估定义了一个分阶段概念,该概念在保持创新潜力的同时包含了最高水平的患者安全。MDR中存在基本要素,可以有针对性地加以实施。必须利用国家实施MDR的3年时间进行积极调整。DGCH由德国科学医学协会联合会(AWMF)在联邦卫生部(BMG)的咨询委员会中代表。目标是通过建立应由医学协会负责的特定注册机构,使国家结构与MDR法规进行负责任的协调。在产品开发规划阶段,早期纳入卫生技术评估对于促成报销的积极决定将具有重要意义。